Previous close | 123.64 |
Open | 122.54 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 122.54 - 122.54 |
52-week range | 122.54 - 122.54 |
Volume | 1 |
Avg. volume | N/A |
Market cap | 3.774B |
Beta (5Y monthly) | 1.94 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.07 |
Earnings date | 04 May 2021 - 10 May 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.